Journal of Cardiology and Cardiovascular Research

Mody R, 2023-J Cardiol Cardiovasc Res
ISSN:2583-259X
Editorial

Emerging Catheter-Based Devices: A New Era for Heart Failure Management

Rohit Mody*

MD, DM, Department of Cardiology, Max Super Specialty Hospital, Bathinda, Punjab, India

***Corresponding Author:** Rohit Mody, MD, DM, Department of Cardiology, Max Super Specialty Hospital, Bathinda, Punjab, India.

Received Date: 04-12-2023
Accepted Date: 04-19-2023
Published Date: 04-28-2023

Keywords: Cardio; Heart failure; Clinical research; Cardiac contractility modulation.

Abbreviations: HF: Heart Failure; CCM: Cardiac Contractility Modulation; ICD: Implantable Cardiac Defibrillator; TASS: Transcatheter Atrial Shunt Systems.

Editorial

Heart failure (HF) remains a major cause of morbidity and mortality worldwide despite advancements in its management. Although existing therapies such as beta-blockers, angiotensin receptor-neprilysin inhibitors, and implantable cardiac defibrillators (ICD) have improved clinical outcomes, the need for more advanced treatment modalities is pressing [1]. Recently, catheter-based devices have emerged as promising interventions, targeting key pathophysiological mechanisms in HF progression [2]. The editorial highlights the potential of these novel devices in managing HF patients and the challenges ahead.

Hemodynamic monitoring devices have become crucial tools in HF management, with notable examples being the Cardio MEMS™ HF System, Cordella™ Pulmonary Artery Pressure Sensor System, and V-LAP™. These devices have demonstrated various clinical benefits, including reductions in HF hospitalizations and improvements in life quality [3]. However, more clinical research is required to address data management challenges and validate their use in HF patients.

Left atrial decompression devices, such as the Corvia Interatrial Shunt and V-Wave Ventura Interatrial Shunt System, have shown promise in reducing mortality rates and improving clinical outcomes in HF patients. More research and clinical trials are needed to demonstrate their long-term efficacy and safety [4].

Transcatheter atrial shunt systems (TASS) like Intershunt, Alleviantm, and NoYA devices have emerged as promising therapeutic interventions for HF patients. Early clinical trials have shown improvements in functional class and reductions in hospitalizations due to HF [5]. Further investigation is needed to evaluate their clinical outcomes.

Citation: Mody R. Emerging Catheter-Based Devices: A New Era for Heart Failure Management. J Cardiol Cardiovasc Res. 2023;4(1):33-34.
DOI: https://doi.org/10.37191/Mapsci-JCCR-4(1)-075

Neuromodulation strategies, such as the Satera Ablation system, have shown potential in improving cardiac hemodynamics, neuromodulation, and restoration of autonomic balance in HF patients. Ongoing clinical trials (NCT04592445) are expected to provide more insight into their safety and efficacy [6].

Catheter-based devices for managing acute decompensated HF, such as the Reitan Catheter Pump and the second heart assist device have demonstrated therapeutic potential in improving parameters like urine output, renal function, and cardiac index. However, limited clinical data exists on their safety and efficacy.

Cardiac contractility modulation (CCM) devices like the Optimizer smart system have gained attention for their potential in treating chronic HF [7]. The clinical role and utilization of CCM in HF treatment may be further defined by the development of combined devices for ICD and CCM.

In conclusion, catheter-based interventions have shown significant potential in managing HF patients who do not respond to guideline-directed medical treatment. However, more research is needed to optimize patient selection, device design, and trial methodologies. As the field continues to evolve, transcatheter devices may play an increasingly important role in addressing the complex mechanisms involved in HF pathogenesis and improving patient outcomes.

References

1. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. N Engl J Med. 2001;345(23):1667-75. PubMed | CrossRef
2. Latib A, Hashim Mustehsan M, Abraham WT, Jorde UP, Bartunek J. Transcatheter Interventions for Heart Failure. Eurointervention. 2023;18(14):1135-49. PubMed | CrossRef
3. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol. 2015;66(13):1431-41. PubMed | CrossRef
4. Alushi B. Atrial Flow Regulator (AFR) Implantation in Patients with Heart Failure and Elevated Filling Pressures: 1-Year Results of a Multicenter Study. Journal Of Interventional Cardiology. 2019.
5. Simard T, Labinaz M, Zahr F, Nazer B, Gray W, Hermiller J, et al. TCT-87 Levoatrial to Coronary Sinus Shunting as a Novel Strategy for Symptomatic Heart Failure: First-In-Human Experience. J Am Coll Cardiol. 2019;74(13S):B87.
6. Málek F, Gajewski P, Zymliński R, Janczak D, Chabowski M, Fudim M, et al. Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction: First-In-Human Clinical Trial. Eur J Heart Fail. 2021;23:1134-43. PubMed | CrossRef
7. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6(10):874-83. PubMed | CrossRef

Citation: Mody R. Emerging Catheter-Based Devices: A New Era for Heart Failure Management. J Cardiol Cardiovasc Res. 2023;4(1):33-34.
DOI: https://doi.org/10.37191/Mapsci-JCCR-4(1)-075